Projects funded by the NCN
PAMAM dendrimer as carrier for mesalazine to enhance the efficacy of inflammatory bowel disease therapy - in vitro studies.
2018/31/N/NZ7/00374
Keywords:
PAMAM dendrimer mesalazine inflammatory bowel disease drug delivery
Descriptors:
- NZ7_14: Pharmacy, pharmacotherapy, pharmacology
- ST5_10: Functional materials/nanomaterials, nanoparticles
Panel:
NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution :
Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska
woj. łódzkie
Principal investigator (from the host institution):
Number of co-investigators in the project: 3
Call: PRELUDIUM 16 - announced on 2018-09-14
Amount awarded: 139 930 PLN
Project start date (Y-m-d): 2019-06-28
Project end date (Y-m-d): 2021-06-27
Project duration:: 24 months (the same as in the proposal)
Project status: Project settled
Project description
Download the project description in a pdf file
Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
- Publication in academic press/journals (1)
- Mesalazine–PAMAM Nanoparticles for Transporter-Independent Intracellular Drug Delivery: Cellular Uptake and Anti-Inflammatory ActivityAuthors:Michal Gorzkiewicz, Monika Marcinkowska, Maciej Studzian, Iwona Karwaciak, Lukasz Pulaski, Barbara Klajnert-MaculewiczAcademic press:International Journal of Nanomedicine (rok: 2023, tom: 18, strony: 2109–2126), Wydawca: Dove Medical PressStatus:PublishedDOI:10.2147/IJN.S390763 - link to the publication